Numbers in millions USD, except per-share numbers.
Neon Therapeutics, Inc.
June 27, 2018
Neon Therapeutics, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial for the treatment of advanced or metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of hormone-receptor-positive breast cancer, as well as NEO-STC-01, a neoantigen adoptive T cell therapy for the treatment of cancers driven or mediated by RAS mutations. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.